Amgen Inc.
$249.48B- Market cap
- $204.01B
- Debt
- +$54.60B
- Cash
- −$9.13B
Capital structure 79% equity / 21% debt · EV / Revenue 6.79x · EV proxy / EBITDA proxy 17.51x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $204.01B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2026 ·
Decision snapshot: AMGN stock price near parity vs PG $377.35 current versus $312.26 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PG's multiple
Implied fair value · at AMGN's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 79% equity / 21% debt · EV / Revenue 6.79x · EV proxy / EBITDA proxy 17.51x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 91% equity / 9% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
The Procter & Gamble Company · implied price per share
Bear
$81.64
Base
$98.63
Bull
$122.06
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
REGENERON PHARMACEUTICALS, INC.
AMGN vs REGN
BIOGEN INC.
AMGN vs BIIB
VERTEX PHARMACEUTICALS INC / MA
AMGN vs VRTX
Gilead Sciences, Inc.
AMGN vs GILD
Moderna, Inc.
AMGN vs MRNA
Eli Lilly and Company
AMGN vs LLY
COLGATE PALMOLIVE CO
AMGN vs CL
KIMBERLY CLARK CORP
AMGN vs KMB
CHURCH & DWIGHT CO INC /DE/
AMGN vs CHD
CLOROX CO /DE/
AMGN vs CLX
Johnson & Johnson
AMGN vs JNJ
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMGN’s faster growth and superior margins deserve a sustained premium over PG, then hold or add only selectively, because the current P/E-based valuation still implies 18.0% downside and the stock already screens above PG-implied fair value.
AMGN is priced at $385.16 versus a P/E-implied value of $315.84, implying 18.0% downside. That gap is notable because AMGN trades above PG-implied range midpoint and also above the DCF range, even though some operating metrics outperform PG.
Supporting Metrics